Compare Fresenius Kabi Onco. with Unichem Lab - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

FRESENIUS KABI ONCO. vs UNICHEM LAB - Comparison Results

FRESENIUS KABI ONCO.     Change

Fresenius Kabi Oncology is the erstwhile Dabur Pharma, which was incorporated in March 2003. The company is a leading player in oncology in India and the international markets. Fresenius Kabi Oncology operates in the regulated markets namely the US a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    FRESENIUS KABI ONCO. UNICHEM LAB FRESENIUS KABI ONCO./
UNICHEM LAB
 
P/E (TTM) x 22.1 -97.6 - View Chart
P/BV x 3.1 0.5 580.9% View Chart
Dividend Yield % 0.0 2.6 -  

Financials

 FRESENIUS KABI ONCO.   UNICHEM LAB
EQUITY SHARE DATA
    FRESENIUS KABI ONCO.
Mar-13
UNICHEM LAB
Mar-19
FRESENIUS KABI ONCO./
UNICHEM LAB
5-Yr Chart
Click to enlarge
High Rs176292 60.3%   
Low Rs79182 43.1%   
Sales per share (Unadj.) Rs37.7167.7 22.5%  
Earnings per share (Unadj.) Rs5.1-3.6 -140.3%  
Cash flow per share (Unadj.) Rs6.75.9 113.2%  
Dividends per share (Unadj.) Rs04.00 0.0%  
Dividend yield (eoy) %01.7 0.0%  
Book value per share (Unadj.) Rs42.5372.3 11.4%  
Shares outstanding (eoy) m158.2370.38 224.8%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x3.41.4 238.9%   
Avg P/E ratio x25.0-65.3 -38.3%  
P/CF ratio (eoy) x18.939.9 47.5%  
Price / Book Value ratio x3.00.6 469.8%  
Dividend payout %0-110.2 0.0%   
Avg Mkt Cap Rs m20,13516,680 120.7%   
No. of employees `0001.22.6 44.3%   
Total wages/salary Rs m7032,393 29.4%   
Avg. sales/employee Rs Th5,176.24,535.2 114.1%   
Avg. wages/employee Rs Th610.4919.8 66.4%   
Avg. net profit/employee Rs Th699.6-98.2 -712.4%   
INCOME DATA
Net Sales Rs m5,96311,801 50.5%  
Other income Rs m18984 1.8%   
Total revenues Rs m5,98112,785 46.8%   
Gross profit Rs m1,430-835 -171.3%  
Depreciation Rs m258674 38.3%   
Interest Rs m-2675 -34.6%   
Profit before tax Rs m1,216-600 -202.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m01 0.0%   
Extraordinary Inc (Exp) Rs m-680-   
Tax Rs m342-343 -99.6%   
Profit after tax Rs m806-256 -315.4%  
Gross profit margin %24.0-7.1 -339.0%  
Effective tax rate %28.157.3 49.1%   
Net profit margin %13.5-2.2 -624.1%  
BALANCE SHEET DATA
Current assets Rs m5,10220,384 25.0%   
Current liabilities Rs m2,3855,029 47.4%   
Net working cap to sales %45.6130.1 35.0%  
Current ratio x2.14.1 52.8%  
Inventory Days Days150105 143.2%  
Debtors Days Days113135 84.0%  
Net fixed assets Rs m5,1489,023 57.1%   
Share capital Rs m158141 112.4%   
"Free" reserves Rs m6,55626,058 25.2%   
Net worth Rs m6,73226,199 25.7%   
Long term debt Rs m9520-   
Total assets Rs m10,38831,496 33.0%  
Interest coverage x-45.8-7.0 656.3%   
Debt to equity ratio x0.10-  
Sales to assets ratio x0.60.4 153.2%   
Return on assets %7.5-0.6 -1,311.3%  
Return on equity %12.0-1.0 -1,227.4%  
Return on capital %14.6-2.0 -730.4%  
Exports to sales %74.569.4 107.3%   
Imports to sales %24.80-   
Exports (fob) Rs m4,4418,188 54.2%   
Imports (cif) Rs m1,477NA-   
Fx inflow Rs m5,2988,188 64.7%   
Fx outflow Rs m1,772596 297.3%   
Net fx Rs m3,5257,592 46.4%   
CASH FLOW
From Operations Rs m1,274-3,278 -38.9%  
From Investments Rs m-1,204-2,860 42.1%  
From Financial Activity Rs m-196-24 810.3%  
Net Cashflow Rs m-126-4,690 2.7%  

Share Holding

Indian Promoters % 0.0 50.1 -  
Foreign collaborators % 81.0 0.0 -  
Indian inst/Mut Fund % 0.3 15.1 2.0%  
FIIs % 9.6 3.0 320.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 31.7 28.7%  
Shareholders   42,599 20,176 211.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare FRESENIUS KABI ONCO. With:   STRIDES PHARMA SCIENCE  AJANTA PHARMA  ALEMBIC LTD  ALKEM LABORATORIES  ELDER PHARMA  

Compare FRESENIUS KABI ONCO. With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 181 Points Higher; Energy and Healthcare Stocks Witness Buying(Closing)

Indian share markets continued to trade on a positive note during closing hours but ended their session off day's high.

Related Views on News

UNICHEM LAB Announces Quarterly Results (1QFY20); Net Profit Up 102.2% (Quarterly Result Update)

Jul 30, 2019 | Updated on Jul 30, 2019

For the quarter ended June 2019, UNICHEM LAB has posted a net profit of Rs 5 m (up 102.2% YoY). Sales on the other hand came in at Rs 2 bn (up 15.4% YoY). Read on for a complete analysis of UNICHEM LAB's quarterly results.

UNICHEM LAB 2018-19 Annual Report Analysis (Annual Result Update)

Jul 4, 2019 | Updated on Jul 4, 2019

Here's an analysis of the annual report of UNICHEM LAB for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of UNICHEM LAB. Also includes updates on the valuation of UNICHEM LAB.

UNICHEM LAB Announces Quarterly Results (4QFY19); Net Profit Up 31.7% (Quarterly Result Update)

May 29, 2019 | Updated on May 29, 2019

For the quarter ended March 2019, UNICHEM LAB has posted a net profit of Rs 37 m (up 31.7% YoY). Sales on the other hand came in at Rs 3 bn (up 35.1% YoY). Read on for a complete analysis of UNICHEM LAB's quarterly results.

UNICHEM LAB Announces Quarterly Results (3QFY19); Net Profit Up 110.9% (Quarterly Result Update)

Feb 4, 2019 | Updated on Feb 4, 2019

For the quarter ended December 2018, UNICHEM LAB has posted a net profit of Rs 63 m (up 110.9% YoY). Sales on the other hand came in at Rs 2 bn (up 53.8% YoY). Read on for a complete analysis of UNICHEM LAB's quarterly results.

UNICHEM LAB Announces Quarterly Results (2QFY19); Net Profit Down 61.4% (Quarterly Result Update)

Nov 5, 2018 | Updated on Nov 5, 2018

For the quarter ended September 2018, UNICHEM LAB has posted a net profit of Rs 177 m (down 61.4% YoY). Sales on the other hand came in at Rs 2 bn (down 42.6% YoY). Read on for a complete analysis of UNICHEM LAB's quarterly results.

More Views on News

Most Popular

The Smartest Stock to Buy for 2020(Profit Hunter)

Nov 14, 2019

Small-cap stocks are selling at bargain prices today and are poised to generate a lot of wealth in 2020 and beyond...

Crash Alert! Is There a Big Bubble in Nestle, HUL and Asian Paints?(Profit Hunter)

Nov 7, 2019

Is this the beginning of the end of multibagger gains in quality stocks like Nestle, HUL, and Asian Paints?

A Trade that Could Generate Profits for Decades

Nov 14, 2019

India's #1 trader is back on the Investor Hour. Vijay Bhambwani talks to us about his super-profitable trading system and shares with us his #1 long term trade. Listen in...

Why Moody's Rating Downgrade is a Strong Sign to Buy Stocks(The 5 Minute Wrapup)

Nov 8, 2019

Investors who took cues from Moody's rating downgrade in 1992 and 2002 created some of the biggest wealth of their lifetime.

The One Trade I'm Most Bullish on Now

Nov 12, 2019

A highly specific trade to potentially triple your money in just three months. You won't find this information anywhere else!

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

FRESENIUS KABI ONCO. SHARE PRICE


Jan 2, 2014 (Close)

TRACK FRESENIUS KABI ONCO.

  • Track your investment in FRESENIUS KABI ONCO. with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON FRESENIUS KABI ONCO.

FRESENIUS KABI ONCO. - PFIZER COMPARISON

COMPARE FRESENIUS KABI ONCO. WITH

MARKET STATS